SCHEMBL19915941

SCHEMBL19915941

FC(F)(F)c1ccc2nnn(-c3ccccc3)c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 4/20 0.50
▸ MAPT P10636 2/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ CTDSP1 Q9GZU7 1/20 0.50
▸ KDM4E B2RXH2 3/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ ALDH1A1 P00352 5/20 0.46
▸ PKM P14618 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ POLB P06746 1/20 0.44
▸ NT5E P21589 2/20 0.43
▸ CYP1A2 P05177 2/20 0.42
▸ KCNMA1 Q12791 1/20 0.41
▸ GRM2 Q14416 2/20 0.41
▸ MAT2A P31153 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19848254 0.88 L3MBTL1 (0.60) L3MBTL1MAPTRAB9ACTDSP1KDM4E
SCHEMBL19848320 0.86 L3MBTL1 (0.46) L3MBTL1MAPTRAB9ACTDSP1KDM4E
SCHEMBL19848735 0.79 NPC1 (0.53) L3MBTL1MAPTRAB9AKDM4ENPC1
SCHEMBL8605903 0.76 NPC1 (0.76) L3MBTL1MAPTRAB9AKDM4ENPC1
SCHEMBL30543440 0.76 NPC1 (0.53) L3MBTL1RAB9AKDM4ENPC1ALDH1A1
SCHEMBL28668108 0.76 NPC1 (0.53) L3MBTL1RAB9AKDM4ENPC1ALDH1A1
SCHEMBL19848719 0.76 KDM4E (0.53) L3MBTL1MAPTKDM4ENPC1ALDH1A1
SCHEMBL11545910 0.76 NPC1 (0.53) L3MBTL1MAPTRAB9AKDM4ENPC1
SCHEMBL19848318 0.75 GRM2 (0.61) L3MBTL1MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL19915872 0.74 PKM (0.56) L3MBTL1MAPTRAB9ACTDSP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-08-25 — — US disclosed
EP-3467930-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY ASAHI KASEI KABUSHIKI KAISHA (JP) 2019-04-10 — — EP disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery BPTF, BRD4, KCNN2 L3MBTL1 2127/4885MAPT 1283/4885RAB9A 3611/4885
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 L3MBTL1 2127/4885MAPT 1283/4885RAB9A 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback